Institut Curie to Evaluate Freenome AI Platform for Analyzing cfDNA in Cancer Patients

Mar 29, 2018

NEW YORK (GenomeWeb) – France's Institut Curie will test the efficacy of Freenome's artificial intelligence-powered genomics platform for studying changes in circulating cell-free DNA to predict patient response to immuno-oncology treatments, the partners said today.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

Feb

21

Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Mar

14

Featured Webinar

A Multiomics Approach to Defining the Nature of Early Malignant Transformations of the Immune System

In this webinar, Dr. Wendy Béguelin of Weill Cornell Medicine will discuss how she used the BD Rhapsody single-cell RNA-seq platform and YFP floxed reporter mouse models to study how lymphoma-associated mutations disrupt the immune system by affecting GC B-cell states, explaining the biology of initiation of low-grade follicular lymphoma.

Main menu